Strategies to induce FOXO3a signaling by targeting PHD1 expression or PHI might have therapeutic potential, especially in chronic kidney diseases and in cancers such as breast cancer, in which the expression of FOXO3a or loss of Cyclin D1 inhibits cell proliferation [47,111]. This evidence concerns the gene FOXO3 and breast carcinoma.